SFA Therapeutics
PrivateLast Round
Series A
Mar 13, 2025
Est. Valuation
$250M
Total Funding Raised
$8.73M
Momentum Score
50 /100
Company Overview
SFA Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops oral, small-molecule therapeutics for autoimmune diseases, chronic inflammatory diseases, and cancer. The company's platform is based on breakthrough research licensed from Temple University and focuses on microbiome-derived metabolites to create drugs that can restore immune homeostasis without causing immunosuppression. Its pipeline includes treatments for conditions such as psoriasis, liver diseases (including MASH/NASH and liver cancer), and other autoimmune disorders. The lead candidate, SFA-002, is an oral drug for psoriasis that has completed Phase 1b clinical trials. The company is venture-backed by investors including Y Combinator, Ben Franklin Technology Partners, and Acequia Capital.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SFA Therapeutics Comps
Public and private peers based on sector, stage, and business model.
SFA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 13, 2025 | ||||
| Debt | Nov 9, 2023 | ||||
| Seed | Jun 20, 2022 | ||||
| Accelerator | Sep 2, 2021 | ||||
| Grant | Jun 24, 2020 | ||||
Seed | Jul 31, 2018 |
Key People
Founding team and executive leadership
SFA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| INP Capital | Seed |
| Benjamin Franklin Technology Partners | Seed |
| Acequia Capital | Seed |
| Ben Franklin Technology Partners of Southeastern Pennsylvania | Grant, Seed |
| Asymmetry Ventures | Seed, Debt |
| Y Combinator | Accelerator |
| Montgomery County, Pennsylvania | Seed, Debt, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 17, 2026
Monthly visitors increased 44% MoM.
- Mar 7, 2025
Presented data for oral psoriasis drug candidate SFA-002 at dermatology conference.
SFA Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about SFA Therapeutics's valuation, stock price, and market status.
